- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04179448
A Comparison of Side Access Mucosal Releasing Incision (SAMRI) and Sulcular Tunnel Access to Treat Gingival Recession.
A Prospective, Randomized Clinical Trial to Compare Side Access Mucosal Releasing Incision (SAMRI) and Sulcular Tunnel Access Procedures With Coronally Advanced Flap and Acellular Dermal Matrix (ADM) to Treat Gingival Recession.
This study will compare two incision designs to allow for coronal gingival/mucosal flap advancement and tissue augmentation with acellular dermal matrix (ADM) graft around teeth with gingival recession and a lack of adequate keratinized gingiva.
The SAMRI technique described is a novel technique involving a simplified incision and suturing technique and to the investigators' knowledge, this is the first study that seeks to compare this technique to other techniques for differences in clinical outcomes (percentage root coverage, resultant tissue thickness, and width of keratinized tissue) and patient-centered outcomes (post-operative pain, swelling, changes in daily activities, and patient-assessed esthetics) in a controlled study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research data and daily clinical observations reveal that teeth with gingival recession and a lack of adequate keratinized tissue (KT) are more prone to persistent gingival inflammation, dentinal sensitivity, radicular (root) caries (tooth decay), faster periodontal attachment loss, and compromised plaque control. Soft tissue grating (by various techniques) aims at changing the quality, quantity and placement of the soft tissue around teeth by covering exposed root surfaces and creating or increasing the zone of keratinized mucosa (KM) surrounding the affected teeth. Both techniques tested have shown good clinical outcomes with regard to root coverage, but clinical reports suggest that decreased intrasurgical time and the simplified protocol of the SAMRI technique may result in improved clinical outcomes and/or a decrease in postoperative morbidity and complications as assessed by patients.
Specific aims for this project include the evaluation of:
- Percentage of root coverage at 6 and 12 months following grafting with SAMRI and sulcular tunnel access with ADM
- KT width at 6 and 12 month following grafting with SAMRI and sulcular tunnel access with ADM
- Change in tissue thickness of the grafted sites at 6 and 12 months
- Practitioner-assessed esthetic outcomes using a standardized pink esthetic scale (PES) at 6 and 12 months postoperatively
- Patient-assessed esthetic outcomes at 6 and 12 months post-operatively
- Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 1 week and 1 month postoperatively
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maria Geisinger, DDS, MS
- Phone Number: 996-7011
- Email: migdds@uab.edu
Study Contact Backup
- Name: Sarah Startley, DMD
- Phone Number: 975-8711
- Email: ss1971@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-0007
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- English speaking
- At least 18 years old
- Must be a patient of the UAB Dental School
- Able to read and understand informed consent document
- One or more adjacent teeth (up to four) with Miller class I or II gingival recession defects and less than or equal to 2mm of KT at each site to be treated.
- Presence of periodontally healthy, non-carious neighboring teeth, healthy implants or edentulous ridges on either side of the involved site(s)
- No anticipated need for restorative care at the teeth to be treated during the study period.
Exclusion Criteria:
- Non-English speaking
- Less than 18 years old
- Smokers/tobacco users (>10 cigarettes/day)
- Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
- Presence of active periodontal disease or radiographic interproximal bone loss or tooth malposition, which would yield a Miller class III or IV categorization for the recession defect.
- Presence of frenulae or other soft tissue anomalies at the site(s) to be treated that, in the opinion of the investigators, will interfere with successful access and treatment of the soft tissue defects.
- Previous soft tissue grafting at the site(s) to be treated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Side Access Mucosal Releasing Incision (SAMRI)
SAMRI incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
|
Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
|
Active Comparator: Sulcular Tunnell access
Sulcular tunnel access incision to allow for coronally advanced flap and placement of acellular dermal matrix (ADM) graft
|
Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of root coverage at 6 and 12 months following grafting with SAMRI and sulcular tunnel access with ADM
Time Frame: From baseline to 6 months and 12 months
|
Compare the change in the exposed root surface at sites with gingival recession.
|
From baseline to 6 months and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
KT width at 6 and 12 month following grafting with SAMRI and sulcular tunnel access with ADM
Time Frame: From baseline to 6 and 12 months
|
Compare the change in keratinized tissue (KT) between two incision designs for root coverage and tissue augmentation.
|
From baseline to 6 and 12 months
|
Change in tissue thickness of the grafted sites at 6 and 12 months
Time Frame: From baseline to 6 and 12 months
|
Using a periodontal probe, soft tissue thickness will be measured (in mm) and compared between FGG and CTG following soft tissue grafting.
|
From baseline to 6 and 12 months
|
Assessed esthetic outcomes using a standardized pink esthetic scale (PES) at 6 and 12 months postoperatively
Time Frame: From baseline to 6 and 12 months
|
Assess esthetic outcomes using an established periodontal esthetic score (PES).
This score evaluates the color of the gum utilizing 5 subscales ranging from 0(worse) to 2 (better) allowing for a summed total score of 10.
|
From baseline to 6 and 12 months
|
Assessed esthetic outcomes at 6 and 12 months post-operatively
Time Frame: At 6 and 12 months postoperatively
|
A visual analogue scale (VAS) based questionnaire regarding esthetic appearance, pain, swelling, bruising, effects on daily activities will be administered.
This measurement ranges from 0-10 (0 being better and 10 being worse).
|
At 6 and 12 months postoperatively
|
Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 1 week and 1 month postoperatively
Time Frame: 1 week, 2 weeks, 1 month, 3 months, 6 months and 12 months postoperatively.
|
A visual analogue scale (VAS) based questionnaire regarding esthetic appearance, pain, swelling, bruising, effects on daily activities.
This measurement ranges from 0-10 (0 being better and 10 being worse).
|
1 week, 2 weeks, 1 month, 3 months, 6 months and 12 months postoperatively.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Maria Geisinger, DDS, MS, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAMRI IRB-300004045
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gingival Recession
-
Case Western Reserve UniversityRecruitingRecession, GingivalUnited States
-
University of LouisvilleRecruitingRecession, GingivalUnited States
-
Krishnadevaraya College of Dental Sciences & HospitalUnknown
-
Universidade Estadual Paulista Júlio de Mesquita...Completed
-
British University In EgyptNot yet recruiting
-
SVS Institute of Dental SciencesCompleted
-
University of LouisvilleCompletedRecession, GingivalUnited States
-
Cairo UniversityUnknownRecession, Gingival
-
Botiss Medical AGCompletedRecession, GingivalSerbia
-
Luis Alberto Chauca BajañaUniversidad de GuayaquilNot yet recruitingGingival Recession | Gingival Recession, Localized
Clinical Trials on STA
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Synta Pharmaceuticals Corp.CompletedNon Small Cell Lung CancerUnited States
-
Synta Pharmaceuticals Corp.CompletedLymphoma | Leukemia | Hematological Malignancies | Metastatic or Unresectable Solid TumorsUnited States
-
David M. Jackman, MDMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...CompletedSmall Cell Lung CancerUnited States
-
University of Alabama at BirminghamActive, not recruitingGingival RecessionUnited States
-
Memorial Sloan Kettering Cancer CenterSynta Pharmaceuticals Corp.Completed
-
Synta Pharmaceuticals Corp.CompletedSolid TumorsUnited States
-
Synta Pharmaceuticals Corp.CompletedAdvanced or Metastatic Solid TumorsUnited States
-
Synta Pharmaceuticals Corp.Completed
-
Massachusetts General HospitalDana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...CompletedEsophagogastric CancerUnited States